Measurement of Antibody Epitope Signatures by Peptide Microarrays to Determine Recency of HIV Infection

通过肽微阵列测量抗体表位特征来确定 HIV 感染的新近程度

• 批准号: 9065192
• 负责人: Timothy Jensen Henrich
• 金额: $ 22.51万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-24 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9065192
• 关键词: AIDS prevention; Algorithms; Allergic Disease; Antibodies; Antibody Diversity; Antibody Response; Avidity; Award; Binding; Binding Sites; Biological Assay; Biological Markers; CD4 Positive T Lymphocytes; Cell Count; Chronic; Communicable Diseases; Complement; Complex; Cross-Sectional Studies; Data; Development; Diagnostic; Dideoxy Chain Termination DNA Sequencing; Epidemic; Epidemiology; Epitope Mapping; Epitopes; Evaluation; Evolution; Foundations; Genome; Goals; HIV; HIV Infections; HIV-1; Immune System Diseases; Immunology; Immunology procedure; Incidence; Individual; Infection; Knowledge; Laboratories; Lead; Longitudinal Studies; Measurement; Measures; Methods; Mission; Modeling; Monitor; Outcome; Peptide Library; Peptides; Performance; Persons; Plasma; Population; Prevention program; Public Health; Qualifying; RNA; Research; Research Project Grants; Resources; Sampling; Serological; Serum; Specificity; Specimen; Staging; Testing; Time; Variant; Viral; Viremia; Work; base; design; expectation; high risk; improved; innovation; novel; prevent; public health intervention; public health relevance; research study; specific biomarkers; tool; transmission process; vaccine trial; virology

 DESCRIPTION (provided by applicant): There is a critical need in HIV research to develop a rapid, inexpensive, and accurate assay that can be used to estimate HIV incidence anywhere in the world and on any sample. In the absence of such a test, it is challenging to identify high risk populations, model transmission, and monitor the outcome of public health interventions. Our long term goal is to develop new methods to measure HIV incidence to improve HIV epidemiology in resource-poor settings. The overall objective of the proposed research is to use a cutting-edge immunologic assay, the global HIV-1 peptide microarray, to define the key epitope signatures of HIV-specific antibodies associated with different stages of HIV infection. Our central hypothesis is that the greater the duration of HIV infection, the greater the diversity of HIV-specific antibodies. The rationale for the proposed research is that, once it is known that antibody epitope signatures are associated with different stages of HIV infection, then the global HIV-1 peptide microarray can be further developed as a tool to measure HIV incidence. Guided by strong preliminary data, this hypothesis will be tested by pursuing two specific aims: 1) to identify the key epitope signatures of HIV-specific antibodies that are associated with three different stages of HIV infection (recent, chronic viremia, and ART suppression); and 2) to determine how HIV serologic diversity is associated with increasing HIV viral diversity in viremic subjects over time. Under the first aim, we will perform antibody epitope mapping with a global HIV-1 peptide microarray on individuals with known time since infection. We will complement the peptide microarray with established incidence assays to measure antibody magnitude and avidity. When the proposed studies have been completed, it is our expectation that the breadth of antibody epitope signatures will be significantly increased in non-recent HIV stages compared to in recent HIV infection. Under the second aim, we will determine the relationship between diversity of HIV epitope- specific antibody responses (as measured by peptide microarray) and HIV viral diversity (as measured by single genome amplification and Sanger sequencing) to provide a better pathogenic understanding of antibody evolution and how it relates to HIV incidence. When these studies have been completed, it is our expectation that the depth of antibody binding (# sequence variants recognized at any given binding site) will be positively associated with increasing HIV viral diversity measures over time. The research proposed in this application is innovative, in our opinion, because it introduces a novel high-throughput antibody-based assay that has the potential to be as sensitive and specific for recent HIV infection as a viral diversity assay. The proposed research is significant, because it is expected to be the demonstration that antibody epitope specificity - as measured by the diversity of antibody binding to HIV peptides - can serve as a biomarker of different stages of HIV infection. Ultimately, such knowledge will inform the design of novel HIV incidence assays that will have broad importance in the fields of HIV epidemiology and diagnostics.

 描述（由申请人提供）：艾滋病毒研究迫切需要开发一种快速、廉价且准确的检测方法，在没有此类检测的情况下，可用于估计世界任何地方的艾滋病毒发病率。识别高风险具有挑战性 我们的长期目标是开发新的方法来衡量艾滋病毒的发病率，以改善资源匮乏地区的艾滋病毒流行病学。边缘免疫学测定，全局 HIV-1 肽微阵列，用于定义与 HIV 感染不同阶段相关的 HIV 特异性抗体的关键表位特征。我们的中心假设是，HIV 感染的持续时间越长，多样性就越大。 拟议研究的基本原理是，一旦知道抗体表位特征与 HIV 感染的不同阶段相关，则可以进一步开发全局 HIV-1 肽微阵列作为测量 HIV 的工具。在强有力的初步数据的指导下，这一假设将通过两个具体目标进行检验：1）确定与 HIV 感染的三个不同阶段（近期、慢性病毒血症和 ART）相关的 HIV 特异性抗体的关键表位特征。 2) 确定 HIV 血清学多样性如何与病毒血症受试者中 HIV 病毒多样性随着时间的推移而增加之间的关系 根据第一个目标，我们将使用全局 HIV-1 肽微阵列对感染后已知时间的个体进行抗体表位作图。将通过已建立的发病率测定来补充肽微阵列，以测量抗体的大小和亲合力。当拟议的研究完成时，我们预计非近期艾滋病毒中抗体表位特征的广度将显着增加。与最近的艾滋病毒感染阶段相比，我们将确定艾滋病毒表位特异性抗体反应的多样性（通过肽微阵列测量）和艾滋病毒病毒多样性（通过单基因组扩增和桑格测序测量）之间的关系。提供对抗体进化及其与 HIV 发病率之间关系的更好的致病性理解。当这些研究完成后，我们期望抗体结合深度（在任何给定结合位点识别的#序列变异）将与增加呈正相关。研究表明，随着时间的推移，艾滋病病毒的多样性会发生变化。我们认为，该申请中提出的方法具有创新性，因为它引入了一种新型的基于抗体的高通量测定法，该测定法对于最近的 HIV 感染具有与病毒多样性测定法一样的敏感性和特异性。拟议的研究意义重大，因为。预计将证明抗体表位特异性（通过抗体与 HIV 肽结合的多样性来衡量）可以作为 HIV 感染不同阶段的生物标志物，最终，这些知识将为新型 HIV 发病率测定的设计提供信息。将在艾滋病毒领域具有广泛的重要性流行病学和诊断。